falsefalse

Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 5

Differentiating Refractory and Relapsed Neuroblastoma

,

Anurag Agrawal, MD, discusses how refractory and relapsed neuroblastoma is differentiated, and the typical treatment approaches for both.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Overview of Neuroblastoma
    EP. 2: Approaches to Diagnosing Neuroblastoma
    EP. 3: Role of CURIE Scores in the Treatment and Management of Neuroblastoma
    EP. 4: Current Treatment Paradigm for Newly Diagnosed Neuroblastoma
    Now Viewing
    EP. 5: Differentiating Refractory and Relapsed Neuroblastoma
    EP. 6: Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
    EP. 7: Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
    EP. 8: Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
    EP. 9: Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
    EP. 10: Future Perspectives in the Treatment of Neuroblastoma

    Related Content:

    Evolving Treatment Strategies in High-Risk NeuroblastomaOncLive News Network®
    Key Areas of Future Research in Advanced Melanoma
    Where RP1 Plus Nivolumab Could Fit in the Treatment Paradigm for Advanced Melanoma Post–PD-1 Inhibition
    Data for RP1 Plus Nivolumab in Metastatic Melanoma After Prior PD-1 Inhibition
    x